Welcome to our dedicated page for Optinose news (Ticker: OPTN), a resource for investors and traders seeking the latest updates and insights on Optinose stock.
Optinose Inc (OPTN) is a specialty pharmaceutical innovator focused on chronic sinusitis treatments through its patented Exhalation Delivery System. This page provides investors and healthcare professionals with essential updates on regulatory developments, clinical research, and corporate milestones.
Track key developments including FDA decisions, peer-reviewed study publications, and partnership announcements. Our curated news collection helps stakeholders monitor progress in ENT-focused drug-device combinations and chronic disease management innovations.
Find verified updates on XHANCE clinical trials, financial earnings reports, and market expansion strategies. All content undergoes strict editorial review to ensure accuracy and relevance for investment research and therapeutic advancement tracking.
Bookmark this page for timely updates on Optinose's novel approaches to nasal drug delivery and specialty pharmaceutical developments. Regularly refreshed content supports informed decision-making for investors and healthcare analysts alike.
Optinose (NASDAQ:OPTN) reported a total revenue of $12.0 million for Q1 2021, boosted by XHANCE net revenues of $11.0 million, a 55% increase from Q1 2020. The number of XHANCE prescriptions surged by 30% to 72,600, while new prescriptions rose by 16% to 25,900. Despite this growth, the company reported a net loss of $26.1 million, or $0.49 per share. Optinose anticipates XHANCE net revenues to reach at least $80 million for full-year 2021, with operating expenses expected between $137 million and $142 million.
Optinose (NASDAQ:OPTN) announced that it will release its first quarter 2021 financial results and corporate updates on May 5, 2021, before market open. A conference call led by the leadership team is scheduled for 8:00 a.m. Eastern Time on the same day. Additionally, CEO Peter Miller will present at the RBC Capital Markets Global Healthcare Conference on May 18, 2021, at 5:25 p.m. Eastern Time. Investors can access the conference call and the subsequent webcast on the company's website.
Optinose (NASDAQ:OPTN) announced that CEO Peter Miller will present a company overview and update at the Needham Virtual Healthcare Conference on April 15, 2021, at 11:45 a.m. ET. The presentation will be available for live streaming on the Optinose Investors page. A recorded version of the webcast will be accessible for 30 days post-event. As a global specialty pharmaceutical company, Optinose focuses on ENT and allergy treatments. For more details about Optinose and their offerings, visit their official website or follow them on social media.
Optinose reported Q4 2020 net revenue of $15.6 million and full-year revenue of $48.4 million from XHANCE. This reflects a 70% increase in prescriptions year-over-year. The company forecasts XHANCE revenue to exceed $80 million in 2021. Clinical trial results for XHANCE as a treatment for Chronic Sinusitis are expected by year-end 2021. Despite a net loss of $23.9 million in Q4 2020, the cash balance was $144.2 million. Optinose anticipates first quarter revenue declines but expects stronger performance later in 2021.
Optinose (NASDAQ:OPTN) will report its fourth quarter 2020 financial results and provide corporate updates on March 3, 2021, before market opening. A conference call with the leadership team is scheduled for 8:00 a.m. Eastern Time on the same day. CEO Peter Miller will present a company overview at the Cowen 41st Annual Health Care Conference on March 4, 2021, at 1:30 p.m. Eastern Time. Investors can access the conference call and webcast through the company's website, with replays available for a limited time.
Optinose (NASDAQ:OPTN) announced the granting of a non-qualified stock option for 15,000 shares to a new employee as an inducement for employment. The stock options were approved by the company’s Compensation Committee and granted outside of the 2010 Stock Incentive Plan, following Nasdaq Rule 5635(c)(4). The options have an exercise price of $4.12, based on the closing price on January 19, 2021, and will vest over four years, contingent on continued employment.
Optinose (NASDAQ: OPTN) announced the granting of non-qualified stock option awards for 35,000 shares of common stock to two new employees. These awards were approved by the Compensation Committee and adhere to Nasdaq Listing Rule 5635(c)(4). The exercise prices for the options are $4.56 and $4.34, reflecting the respective closing prices on the grant dates of December 7 and December 14, 2020. The options have a 10-year term and vest over four years, contingent upon continued service with the company.
Optinose (NASDAQ:OPTN) announced the appointment of Tomas J. Heyman as a new director, bringing extensive pharmaceutical industry experience, particularly in business development. He previously led Johnson & Johnson's venture capital group, managing around $1.5 billion in investments. William F. Doyle, a longstanding board member since 2010, will resign after the December 11, 2020 board meeting. Doyle played a crucial role in the strategic direction leading to FDA-approved products using Optinose's Exhalation Delivery System.
Optinose reported Q3 2020 net revenues of $15.4 million, a significant increase from $8.7 million in Q3 2019, driven by a 61% rise in total prescriptions for XHANCE. New prescriptions surged 23% from Q2 2020. The company exceeded its debt facility revenue threshold, allowing for an additional $20 million drawdown to bolster its cash position. However, net losses for the quarter were $21.2 million, or $0.43 per share. Optinose also anticipates $127-$132 million in total operating expenses for 2020, down from previous guidance.
FAQ
What is the current stock price of Optinose (OPTN)?
What is the market cap of Optinose (OPTN)?
